Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials

The Lancet Oncology

Volumn 17, Issue 7, 2016, Pages e294-e304

  Ghislain, Irina ^a   Zikos, Efstathios ^b   Coens, Corneel ^a   Quinten, Chantal ^b   Balta, Vasiliki ^c   Tryfonidis, Konstantinos ^a   Piccart, Martine ^d   Zardavas, Dimitrios ^e   Nagele, Eva ^f   Bjelic Radisic, Vesna ^f   Cardoso, Fatima ^g   Sprangers, Mirjam A G ^h   Velikova, Galina ⁱ   Bottomley, Andrew ^a  

^a EORTC DATA CENTER   (Belgium)

^b EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d JULES BORDET INSTITUTE   (Belgium)

^e Breast International Group   (Belgium)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g CHAMPALIMAUD CLINICAL CENTER   (Portugal)

^h ACADEMIC MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE CORE QUESTIONNAIRE 30 ITEMS; EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE BREAST CANCER MODULE 23 ITEMS; EUROQOL FIVE DIMENSION SCALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY QUESTIONNAIRE FOR BREAST SYMPTOM; HUMAN; METASTATIC BREAST CANCER; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ROTTERDAM SYMPTOM CHECKLIST; SYSTEMATIC REVIEW; BREAST NEOPLASMS; FEMALE; PROCEDURES; QUESTIONNAIRE; SECONDARY;

BREAST NEOPLASMS; FEMALE; HUMANS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVEYS AND QUESTIONNAIRES;

EID: 84991108750     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30099-7     Document Type: Review

References (79)

1. 1 Torre, LA, Bray, F, Siegel, RL, Ferlay, J, Lortet-Tieulent, J, Jemal, A, Global cancer statistics, 2012. CA Cancer J Clin 65 (2015), 87–108.
2. 2 Tryfonidis, K, Senkus, E, Cardoso, MJ, Cardoso, F, Management of locally advanced breast cancer-perspectives and future directions. Nat Rev Clin Oncol 12 (2015), 147–162.
3. 3 Cardoso, F, Costa, A, Norton, L, et al. the European School of Oncology, the European Society of Medical Oncology. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast 23 (2014), 489–502.
4. 4 Cardoso, F, Costa, A, Norton, L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol 25 (2014), 1871–1888.
5. 5 Senkus, E, Cardoso, F, Pagani, O, Time for more optimism in metastatic breast cancer?. Cancer Treat Rev 40 (2014), 220–228.
6. 6 Smith, I, Goals of treatment for patients with metastatic breast cancer. Semin Oncol 33:suppl 2 (2006), S2–S5.
7. 7 Bottomley, A, Flechtner, H, Efficace, F, et al., the European Organisation for Research and Treatment of Cancer (EORTC) Data Center and Quality of Life Group. Health related quality of life outcomes in cancer clinical trials. Eur J Cancer 41 (2005), 1697–1709.
8. 8 Zardavas, D, Baselga, J, Piccart, M, Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol 10 (2013), 191–210.
9. 9 Niraula, S, Amir, E, Vera-Badillo, F, Seruga, B, Ocana, A, Tannock, IF, Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis. J Clin Oncol 32 (2014), 3634–3642.
10. 10 A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies. http://www.ncbi.nlm.nih.gov/pubmed/?term=Annals+of+Oncology26%3A+1547%E2%80%931573%2C+2015, 2015 (accessed Jan 19, 2016).
11. 11 Cherny, NI, Sullivan, R, Dafni, U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 26 (2015), 1547–1573.
12. 12 Bottomley, A, Therasse, P, Quality of life in patients undergoing systemic therapy for advanced breast cancer. Lancet Oncol 3 (2002), 620–628.
13. 13 Lee, CW, Chi, KN, The standard of reporting of health-related quality of life in clinical cancer trials. J Clin Epidemiol 53 (2000), 451–458.
14. 14 Efficace, F, Osoba, D, Gotay, C, Sprangers, M, Coens, C, Bottomley, A, Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making. Ann Oncol 18 (2007), 775–781.
15. 15 Brundage, M, Bass, B, Davidson, J, et al. Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers. Qual Life Res 20 (2011), 653–664.
16. 16 Efficace, F, Bottomley, A, Osoba, D, et al. Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials–does HRQOL evaluation in prostate cancer research inform clinical decision making?. J Clin Oncol 21 (2003), 3502–3511.
17. 17 Calvert, M, Blazeby, J, Altman, DG, Revicki, DA, Moher, D, Brundage, MD, the CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 309 (2013), 814–822.
18. 18 Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March, 2011]). Cochrane Collab, 2011. Julian PT Higgins and Sally Green.
19. 19 Claassens, L, van Meerbeeck, J, Coens, C, et al. Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials. J Clin Oncol 29 (2011), 2104–2120.
20. 20 Zikos, E, Ghislain, I, Coens, C, et al. Health-related quality of life in small-cell lung cancer: a systematic review on reporting of methods and clinical issues in randomised controlled trials. Lancet Oncol 15 (2014), e78–e89.
21. 21 Bottomley, A, Therasse, P, Piccart, M, et al. the European Organisation for Research and Treatment of Cancer Breast Cancer Group the National Cancer Institute of Canada, the Swiss Group for Clinical Cancer Research. Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial. Lancet Oncol 6 (2005), 287–294.
22. 22 Bottomley, A, Biganzoli, L, Cufer, T, et al., the European Organization for Research and Treatment of Cancer Breast Cancer Group. Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study. J Clin Oncol 22 (2004), 2576–2586.
23. 23 Burris, HA 3rd, Lebrun, F, Rugo, HS, et al. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer 119 (2013), 1908–1915.
24. 24 Cortés, J, Baselga, J, Im, Y-H, et al. Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Ann Oncol 24 (2013), 2630–2635.
25. 25 Chia, S, Gradishar, W, Mauriac, L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior non-steroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 26 (2008), 1664–1670.
26. 26 Chan, S, Romieu, G, Huober, J, et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol 27 (2009), 1753–1760.
27. 27 Park, YH, Jung, KH, Im, S-A, et al. Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. J Clin Oncol 31 (2013), 1732–1739.
28. 28 Park, IH, Lee, KS, Kim, JH, et al. Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02). Breast Cancer Res Treat 152 (2015), 77–85.
29. 29 Nuzzo, F, Morabito, A, Gravina, A, et al. Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial. BMC Cancer, 11, 2011, 75.
30. 30 Liu, J, Tu, D, Dancey, J, et al. Quality of life analyses in a clinical trial of DPPE (tesmilifene) plus doxorubicin versus doxorubicin in patients with advanced or metastatic breast cancer: NCIC CTG Trial MA.19. Breast Cancer Res Treat 100 (2006), 263–271.
31. 31 Jones, SE, Erban, J, Overmoyer, B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23 (2005), 5542–5551.
32. 32 Fountzilas, G, Kalofonos, HP, Dafni, U, et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 15 (2004), 1517–1526.
33. 33 Conte, PF, Guarneri, V, Bruzzi, P, et al., the Gruppo Oncologico Nord Ovest. Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial. Cancer 101 (2004), 704–712.
34. 34 Keller, AM, Mennel, RG, Georgoulias, VA, et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 22 (2004), 3893–3901.
35. 35 O'Shaughnessy, J, Miles, D, Vukelja, S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20 (2002), 2812–2823.
36. 36 Lück, H-J, Du Bois, A, Loibl, S, et al. Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. Breast Cancer Res Treat 139 (2013), 779–787.
37. 37 Bachelot, T, Bajard, A, Ray-Coquard, I, et al. Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer. Oncology 80 (2011), 262–268.
38. 38 Walker, LG, Eremin, JM, Aloysius, MM, et al. Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer. BMC Cancer, 11, 2011, 179.
39. 39 Svensson, H, Einbeigi, Z, Johansson, H, Hatschek, T, Brandberg, Y, Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine). Breast Cancer Res Treat 123 (2010), 785–793.
40. 40 Meier, CR, Illiger, H-J, Steder, M, et al. Weekly vinorelbine versus docetaxel for metastatic breast cancer after failing anthracycline treatment. Onkologie 31 (2008), 447–453.
41. 41 Crump, M, Gluck, S, Tu, D, et al. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol 26 (2008), 37–43.
42. 42 Karamouzis, MV, Ioannidis, G, Rigatos, G, Quality of life in metastatic breast cancer patients under chemotherapy or supportive care: a single-institution comparative study. Eur J Cancer Care (Engl) 16 (2007), 433–438.
43. 43 Cassier, PA, Chabaud, S, Trillet-Lenoir, V, et al. A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study. Breast Cancer Res Treat 109 (2008), 343–350.
44. 44 von Minckwitz, G, Chernozemsky, I, Sirakova, L, et al. Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anticancer Drugs 16 (2005), 871–877.
45. 45 Winer, EP, Berry, DA, Woolf, S, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 22 (2004), 2061–2068.
46. 46 Nabholtz, J-M, Falkson, C, Campos, D, et al., the TAX 306 Study Group. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 21 (2003), 968–975.
47. 47 Sledge, GW, Neuberg, D, Bernardo, P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21 (2003), 588–592.
48. 48 Heidemann, E, Stoeger, H, Souchon, R, et al. Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. Ann Oncol 13 (2002), 1717–1729.
49. 49 Del Mastro, L, Fabi, A, Mansutti, M, et al. Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments. BMC Cancer, 13, 2013, 164.
50. 50 Corey-Lisle, PK, Peck, R, Mukhopadhyay, P, et al. Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer. Cancer 118 (2012), 461–468.
51. 51 Hopwood, P, Watkins, J, Ellis, P, Smith, I, Clinical interpretation of quality-of-life outcomes: an investigation of data from the randomized trial of gemcitabine plus paclitaxel compared with paclitaxel alone for advanced breast cancer. Breast J 14 (2008), 228–235.
52. 52 Schröder, CP, de Munck, L, Westermann, AM, et al. Weekly docetaxel in metastatic breast cancer patients: no superior benefits compared to three-weekly docetaxel. Eur J Cancer 47 (2011), 1355–1362.
53. 53 Osoba, D, Slamon, DJ, Burchmore, M, Murphy, M, Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 20 (2002), 3106–3113.
54. 54 Welslau, M, Diéras, V, Sohn, J-H, et al. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Cancer 120 (2014), 642–651.
55. 55 Hurvitz, SA, Dirix, L, Kocsis, J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 31 (2013), 1157–1163.
56. 56 Brufsky, A, Hoelzer, K, Beck, T, et al. A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer. Clin Breast Cancer 11 (2011), 211–220.
57. 57 Zhou, X, Cella, D, Cameron, D, et al. Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat 117 (2009), 577–589.
58. 58 Gianni, L, Romieu, GH, Lichinitser, M, et al. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 31 (2013), 1719–1725.
59. 59 Wu, Y, Amonkar, MM, Sherrill, BH, et al. Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Ann Oncol 22 (2011), 2582–2590.
60. 60 Fountzilas, G, Dafni, U, Dimopoulos, MA, et al. A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat 115 (2009), 87–99.
61. 61 Miller, K, Wang, M, Gralow, J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 (2007), 2666–2676.
62. 62 Miller, KD, Chap, LI, Holmes, FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005), 792–799.
63. 63 Eiermann, W, International Herceptin Study Group. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. Ann Oncol 12:suppl 1 (2001), S57–S62.
64. 64 Di Leo, A, Jerusalem, G, Petruzelka, L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 28 (2010), 4594–4600.
65. 65 Ellis, MJ, Gao, F, Dehdashti, F, et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA 302 (2009), 774–780.
66. 66 Howell, A, Robertson, JF, Quaresma Albano, J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20 (2002), 3396–3403.
67. 67 Osborne, CK, Pippen, J, Jones, SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20 (2002), 3386–3395.
68. 68 Sherrill, B, Di Leo, A, Amonkar, MM, et al. Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. Curr Med Res Opin 26 (2010), 767–775.
69. 69 Sherrill, B, Amonkar, MM, Sherif, B, Maltzman, J, O'Rourke, L, Johnston, S, Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib. Oncologist 15 (2010), 944–953.
70. 70 Vogel, BCL, Cobleigh, MA, Tripathy, D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002), 719–726.
71. 71 Bottomley, A, Vachalec, S, Bjordal, K, Blazeby, J, Flechtner, H, Ruyskart, P, The development and utilisation of the European Organisation for research and treatment of cancer quality of life group item bank. Eur J Cancer 38 (2002), 1611–1614.
72. 72 Guidance on posting and publication of result-related information on clinical trials in relation to the implementation of Article 57(2) of Regulation (EC) No 726/2004 and Article 41(2) of Regulation (EC) No 1901/2006. http://ec.europa.eu/health/files/eudralex/vol-10/2012_302-03/2012_302-03_en.pdf (accessed June 6, 2016).
73. 73 US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf, 2009 (accessed June 6, 2016).
74. 74 European Medicines Agency. Committee for Medicinal Products for Human Use. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. http://www.ema.europa.eu/docs/en_GB/document_library/ Scientific_guideline/2009/09/WC500003637.pdf, July 27, 2005 (accessed June 6, 2016).
75. 75 Zardavas, D, Pugliano, L, Piccart, M, Personalized therapy for breast cancer: a dream or a reality?. Future Oncol 9 (2013), 1105–1119.
76. 76 Alexandros, G, Sfakianakis, Systematic review of the side effects associated with anti-HER2-targeted therapies used in the treatment of breast cancer, on behalf of the EORTC Quality of Life Group. https://sfakianakismedblog.wordpress.com/2015/12/19/systematic-review-of-the-side-effects-associated-with-anti-her2-targeted-therapies-used-in-the-treatment-of-breast-cancer-on-behalf-of-the-eortc-quality-of-life-group-2/, 2015 (accessed Jan 21, 2016).
77. 77 European Medicines Agency. Reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies. Eur Med Agency Sci Med Heal 44 (2014), 1–9.
78. 78 Goodwin, PJ, Black, JT, Bordeleau, LJ, Ganz, PA, Health-related quality-of-life measurement in randomized clinical trials in breast cancer–taking stock. J Natl Cancer Inst 95 (2003), 263–281.
79. 79 Adamowicz, K, Jassem, J, Katz, A, Saad, ED, Assessment of quality of life in advanced breast cancer. An overview of randomized phase III trials. Cancer Treat Rev 38 (2012), 554–558.